HER2/CEP17 ratio and HER2 immunohistochemistry predict clinical outcome after first-line trastuzumab plus taxane chemotherapy in patients with HER2 fluorescence in situ hybridization-positive metastatic breast cancer
Titel:
HER2/CEP17 ratio and HER2 immunohistochemistry predict clinical outcome after first-line trastuzumab plus taxane chemotherapy in patients with HER2 fluorescence in situ hybridization-positive metastatic breast cancer
Auteur:
Kim, Ji-Won Kim, Jee Hyun Im, Seock-Ah Kim, Yu Jung Han, Hye-Suk Kim, Jin-Soo Lee, Kyung-Hun Kim, Tae-Yong Han, Sae-Won Jeon, Yoon Kyung Oh, Do-Youn Kim, Tae-You Park, In Ae